Sermorelin

Sermorelin (GHRH(1-29)) is a truncated GHRH (29 amino acids). The HEIVE catalog describes it as: The shortest fragment of natural GHRH that still works. It was a licensed medicine with a paediatric safety record before it was withdrawn commercially. It is also known as GRF 1-29.

HEIVE groups Sermorelin under fatigue, sleep, metabolic health, bone density and healthspan. These catalog categories are not approved indications or evidence that treatment works. See the product-specific regulatory answer below.

Historically. Geref products were approved for pediatric growth-hormone deficiency and diagnostic use. Approval was withdrawn in 2009 after discontinuation; FDA later determined withdrawal was not for safety or effectiveness. This does not establish approval of currently compounded sermorelin.

• FDA product data (October 6, 2026)
• FDA Geref withdrawal determination

The HEIVE editorial risk summary for Sermorelin lists: Flushing, injection-site itch, occasional headache in the first week. Longer-term concerns: It works through your own pituitary, so the ceiling is physiological. Lower risk than direct GH, not zero. This is not a complete or clinically reviewed safety assessment; risks depend on the product, route and population.

Sermorelin has no single onset time established by this catalog. The editorial timeline starts with “Days 1–7”. These are illustrative model or editorial milestones, not clinically validated outcome predictions.

HEIVE's illustrative catalog entry for Sermorelin: 200–300 mcg subcutaneously before bed, on an empty stomach. This is not a verified study range or a prescription. A dose cannot be transferred between products, routes or indications; use the specific approved label and the prescribing clinician's instructions where applicable.

The catalog classifies Sermorelin as having human research. Its paper-count snapshot is not a live PubMed search, a count of controlled human trials or proof of safety. This FAQ has not independently validated the catalog's clinical literature claims.

The source catalog lists sublingual for Sermorelin. A listed form is not evidence of an approved or effective treatment.

Preparation of Sermorelin depends on the exact labeled product. Follow its instructions for formulation, diluent, route and storage. A generic powder recipe must not be applied to a prefilled, ready-to-use or differently formulated product. The catalog's mixing example does not establish sterility or stability.

Storage for Sermorelin depends on the specific formulation (injectable and sublingual in the source catalog). Follow the product's labeled temperature, light protection and expiry or discard instructions. A general refrigerator or 28-day rule does not establish stability or sterility for every preparation.

The HEIVE editorial summary for Sermorelin: Nightly dosing, cycled 12 weeks on and four off. This summary is not a clinically validated prediction of tolerance or withdrawal for an individual.

Sermorelin and Ipamorelin share the catalog categories fatigue, sleep and metabolic health. Sermorelin: The shortest fragment of natural GHRH that still works. It was a licensed medicine with a paediatric safety record before it was withdrawn commercially. Ipamorelin: A selective growth-hormone releasing peptide with little effect on cortisol or prolactin. This is a catalog comparison, not a head-to-head clinical result or a recommendation to substitute treatments.

• View Ipamorelin

The HEIVE editorial summary highlights: Sleep-depth reports improved more reliably than any body-composition marker. The cited study, population and formulation must be checked before treating this summary as a clinical finding; this FAQ does not supply a verified research citation for it.